β-agonists and metabolism

Journal of Allergy and Clinical Immunology

Volumn 110, Issue 6 SUPPL., 2002, Pages

  Philipson, L H ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Adipocyte metabolism; Glucose metabolism; Hypoglycemia unawareness; Insulin secretion; agonist

Indexed keywords

BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; GLUCAGON; GLUCOSE; GLYCOGEN; INSULIN;

ADIPOCYTE; BETA ADRENERGIC STIMULATION; CONFERENCE PAPER; DRUG EFFECT; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; METABOLISM; PANCREAS CELL; PRIORITY JOURNAL; REGULATORY MECHANISM;

EID: 0036907406     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2002.129702     Document Type: Conference Paper

References (41)

1. Leff AR. Identifying patients at risk from the use of beta-adrenergic agonists. Am J Respir Crit Care Med 1996;154:1593.
2. 2-sympathomimetic drug, on maternal glucose, insulin, glucagon, and free fatty acid levels. Am J Obstet Gynecol 1978;130:761-4.
3. Palmer JP, Halter J, Werner PL. Differential effect of isoproterenol on acute glucagon and insulin release in man. Metabolism 1979;28:237-40.
4. Smigaj D, Roman-Drago NM, Amini SB, Caritis SN, Kalhan SC, Catalano PM. The effect of oral terbutaline on maternal glucose metabolism and energy expenditure in pregnancy. Am J Obstet Gynecol 1998;178:1041-7.
5. Guhan AR, Cooper S, Oborne J, Lewis S, Bennett J, Tattersfield AE. Systemic effects of formoterol and salmeterol: A dose-response comparison in healthy subjects. Thorax 2000;55:650-6.
6. Bremner P, Woodman K, Burgess C, Crane J, Purdie G, Pearce N, et al. A comparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol. Eur Respir J 1993;6:204-10.
7. Burgess C, Ayson, Rajasingham S, Crane J, Della Cioppa G, Till MD. The extrapulmonary effects of increasing doses of formoterol in patients with asthma. Eur J Clin Pharmacol 1998;54:141-7.
8. Polonsky KS. Lilly Lecture 1994. The beta-cell in diabetes: From molecular genetics to clinical research. Diabetes 1995;44:705-17.
9. Bressler R, Cordon MV. The effect of β-adrenergic receptor blocking agents on drug-induced insulin secretion. Adv Metab Disord 1970;1(suppl):87-94.
10. Loubatieres A, Mariani MM, Sorel G, Savi L. The action of β-adrenergic blocking and stimulating agents on insulin secretion. Characterization of the type of β receptor. Diabetologia 1971;7:127-32.
11. Sumi T, Ui M. Potentiation of the adrenergic β-receptor-mediated insulin secretion in pertussis-sensitized rats. Endocrinology 1975;97:352-8.
12. Lacey RJ, Berrow NS, London NJM, Lake SP, James RF, Scarpello JHB, et al. Differential effects of β-adrenergic agonists on insulin secretion from pancreatic islets isolated from rat and man. J Mol Endocrinol 1990;5:49-54.
13. Bernal-Mizrachi E, Wen W, Stahlhut S, Welling CM, Permutt MA. Islet β cell expression of constitutively active Akt1/PKBα induces striking hypertrophy, hyperplasia, and hyperinsulinemia. J Clin Invest 2001;108:1631-8.
14. Tuttle RL, Gill NS, Pugh W, Lee J-P, Koeberlein B, Furth EE, Polonsky KS, et al. Regulation of pancreatic β-cell growth and survival by the serine/threonine protein kinase Akt1/PKBα. Nat Med 2001;7:1133-7.
15. Nonogaki K. New insights into sympathetic regulation of glucose and fat metabolism. Diabetologia 2000;43:533-49.
16. Shulman GI. Cellular mechanisms of insulin resistance in humans. Am J Cardiol 1999;84:3J-10J.
17. 2-adrenergic receptor-selective agonist clenbuterol prevents Fas-induced liver apoptosis and death in mice. Am J Physiol 1999;276:G647-54.
18. Pan SJ, Hancock J, Ding Z, Fogt D, Lee M, Ivy JL. Effects of clenbuterol on insulin resistance in conscious obese Zucker rats. Am J Physiol Endocrinol Metab 2001;280:E554-61.
19. 2-adrenergic agonist treatment possible muscle specific contributions. Life Sci 2001;69:599-611.
20. Johnson ES, Koepsell TD, Reiber G, Stergachis A, Platt R. Increasing incidence of serious hypoglycemia in insulin users. J Clin Epidemiol 2002;55:253-9.
21. Allen C, LeCaire T, Palta M, Daniels K, Meredith M, D'Alessio DJ, for the Wisconsin Diabetes Registry Project. Risk factors for frequent and severe hypoglycemia in type 1 diabetes. Diabetes Care 2001;24:1878-81.
22. Cryer PE. Glucose counterregulation: Prevention and correction of hypoglycemia in humans. Am J Physiol 1993;264:E149-55.
23. Shapiro AMJ, Lakey JRT, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000;343:230-8.
24. Bolli G, de Feo P, Compagnucci P, Cartechini MG, Angeletti G, Santeusanio F, et al. Abnormal glucose counterregulation in insulin-dependent diabetes mellitus: Interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion. Diabetes 1983;32:134-41.
25. Ovalle F, Fanelli CG, Paramore DS, Hershey T, Craft S, Cryer PE. Brief twice-weekly episodes of hypoglycemia reduce detection of clinical hypoglycemia in type 1 diabetes mellitus. Diabetes 1998;47:1472-9.
26. Korytkowski MT, Mokan M, Veneman TF, Mitrakou A, Cryer PE, Gerich JE. Reduced β-adrenergic sensitivity in patients with type 1 diabetes and hypoglycemia unawareness. Diabetes Care 1998;21:1939-43.
27. Vea H, Trovik TS, Sager G, Birkeland K, Revhaug A, Sundsfjord J, et al. Return of β-adrenergic sensitivity in a patient with insulinoma after removal of the tumour. Diabet Med 1997;14:979-84.
28. Fritsche A, Stumvoll M, Häring HU, Gerich JE. Reversal of hypoglycemia unawareness in a long-term type 1 diabetic patient by improvement of β-adrenergic sensitivity after prevention of hypoglycemia. J Clin Endocrinol Metab 2000;85:523-5.
29. Fritsche A, Stefan N, Häring H, Gerich J, Stumvoll M. Avoidance of hypoglycemia restores hypoglycemia awareness by increasing β-adrenergic sensitivity in type 1 diabetes. Ann Intern Med 2001;134:729-36.
30. Saleh TY, Cryer PE. Alanine and terbutaline in the prevention of nocturnal hypoglycemia in IDDM. Diabetes Care 1997;20:1231-6.
31. Pandey SC. Neuronal signaling systems and ethanol dependence. Mol Neurobiol 1998;17:1-15.
32. Liggett SB. Pharmacogenetics of β-1- and β-2-adrenergic receptors. Pharmacology 2000;61:167-73.
33. Evans WE, Johnson JA. Pharmacogenomics: The inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2001;2:9-39.
34. 2-adrenergic receptor variation in human hypertension. Curr Hypertens Rep 2000;2:39-43.
35. Port JD, Bristow MR. Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol 2001;33:887-905.
36. Joos L, Sandford AJ. Genotype predictors of response to asthma medications. Curr Opin Pulm Med 2002;8:9-15.
37. 3-adrenoceptors. Br J Clin Pharmacol 1996;42:291-300.
38. Christiansen C, Poulsen P, Beck-Nielsen H. The Trp64Arg mutation of the adrenergic β-3 receptor gene impairs insulin secretion: A twin study. Diabet Med 1999;16:835-40.
39. 3-adrenergic receptor. Arch Med Res 1999;30:459-64.
40. Walston J, Silver K, Hilfiker H, Andersen RE, Seibert M, Beamer B, et al. Insulin response to glucose is lower in individuals homozygous for the Arg 64 variant of the β-3-adrenergic receptor. J Clin Endocrinol Metab 2000;85:4019-22.
41. 3-adrenoceptor knockout mice: Evidence for a new β-adrenergic receptor in brown adipose tissue. Br J Pharmacol 1998;124:1684-8.